TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice

Gut

Volumn 64, Issue 12, 2015, Pages 1961-1971

  Martin, Perrine ^a   Dubois, Clarisse ^a   Jacquier, Emilie ^a   Dion, Sarah ^b   Mancini Bourgine, Maryline ^b   Godon, Ophélie ^b   Kratzer, Roland ^a   Lelu Santolaria, Karine ^a   Evlachev, Alexei ^a   Meritet, Jean François ^c   Schlesinger, Yasmin ^a   Villeval, Dominique ^a   Strub, Jean Marc ^d   Van Dorsselaer, Alain ^d   Marchand, Jean Baptiste ^a   Geist, Michel ^a   Brandely, Renée ^a   Findeli, Annie ^a   Boukhebza, Houda ^a   Menguy, Thierry ^a   Silvestre, Nathalie ^a   Michel, Marie Louise ^b   Inchauspé, Geneviève ^a   more..

^a TRANSGENE S A   (France)

^b INSTITUT PASTEUR   (France)

^c Institut Cochin   (France)

^d UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; TG1050; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS DNA; DNA DIRECTED DNA POLYMERASE; HEPATITIS B CORE ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; TUMOR NECROSIS FACTOR; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN;

ADENOVIRIDAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS B; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROTYPE; T LYMPHOCYTE; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CLASSIFICATION; DISEASE MODEL; GENE VECTOR; GENETICS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; LYMPHOCYTE COUNT; METABOLISM; PROCEDURES; TIME FACTOR; TRANSGENIC MOUSE;

ADENOVIRIDAE; ALANINE TRANSAMINASE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; GENE PRODUCTS, ENV; GENETIC VECTORS; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HLA-A2 ANTIGEN; IMMUNOTHERAPY; INTERFERON-GAMMA; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL FUSION PROTEINS; VIRAL LOAD;

EID: 84938109131     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-308041     Document Type: Article

References (52)

1. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
2. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19.
3. Buti M. HBeAg-positive chronic hepatitis B: why do I treat my patients with nucleos (t)ide analogs? Liver Int 2014;34(Suppl 1):108-11.
4. Vigano M, Mangia G, Lampertico P. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Liver Int 2014;34(Suppl 1):120-6.
5. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2014;34(Suppl 1):112-19.
6. Vlachogiannakos J, Papatheodoridis GV. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?. Liver Int 2014;34(Suppl 1):127-32.
7. Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991;88:10445-9.
8. Rehermann B, Fowler P, Sidney J, et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995;181:1047-58.
9. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-64.
10. Das A, Hoare M, Davies N, et al. Functional skewing of the global CD8T cell population in chronic hepatitis B virus infection. J Exp Med 2008;205:2111-24.
11. Lopes AR, Kellam P, Das A, et al. Bim-mediated deletion of antigen-specific CD8T cells in patients unable to control HBV infection. J Clin Invest 2008;118:1835-45.
12. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol 2010;52:616-19.
13. Godon O, Fontaine H, Kahi S, et al. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2014;22:675-84.
14. Yang SH, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study. Gene Ther 2006;13:1110-17.
15. Liu J, Kosinska A, Lu M, et al. New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 2014;29:10-16.
16. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011;54:1286-96.
17. Dion S, Bourgine M, Godon O, et al. Adeno-associated virus-mediated gene transfer leads to persistent hepatitis B virus replication in mice expressing HLA-A2 and HLA-DR1 molecules. J Virol 2013;87:5554-63.
18. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-51.
19. Pajot A, Michel ML, Fazilleau N, et al. A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004;34:3060-9.
20. Chartier C, Degryse E, Gantzer M, et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996;70:4805-10.
21. Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-17.
22. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22.
23. Boukhebza H, Dubois C, Koerper V, et al. Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models. Vaccine. 2014;32:3256-63.
24. Fournillier A, Gerossier E, Evlashev A, et al. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007;25:7339-53.
25. Maini MK, Boni C, Ogg GS, et al. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology 1999;117:1386-96.
26. Penna A, Chisari FV, Bertoletti A, et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991;174:1565-70.
27. Hikono H, Kohlmeier JE, Takamura S, et al. Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J Exp Med 2007;204:1625-36.
28. Rollier CS, Reyes-Sandoval A, Cottingham MG, et al. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011;23:377-82.
29. Bassett JD, Swift SL, Bramson JL. Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev Vaccines 2011;10:1307-19.
30. Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614-24.
31. Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004;78:5707-19.
32. Asabe S, Wieland SF, Chattopadhyay PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009;83:9652-62.
33. Thimme R, Wieland S, Steiger C, et al. CD8 + T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003;77:68-76.
34. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
35. Yang PL, Althage A, Chung J, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 2010;107:798-802.
36. Wieland SF, Spangenberg C, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA 2004;101:2129-34.
37. Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8 T cells: implications for their use as vaccines. Blood 2007;110:1916-23.
38. Steffensen MA, Holst PJ, Steengaard SS, et al. Qualitative and quantitative analysis of adenovirus-type 5 vector induced memory CD8T cells: not as bad as their reputation. J Virol 2013;87:6283-95.
39. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-93.
40. Tamminga C, Sedegah M, Regis D, et al. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 2011;6:e25868.
41. Smaill F, Jeyanathan M, Smieja M, et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci Transl Med 2013;5:205ra134.
42. Wortmann A, Vöhringer S, Engler T, et al. Fully detargeted polyethylene glycol-coated adenoviru vectors are potent genetic vaccines and escape pre-existing anti-adenovirus antibodies. Mol Ther 2008;15:154-62.
43. Yang FQ, Lee CG, Park SH, et al. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis V carriers: a proof-of-concept study. Gene Ther 2006;13:1110-17.
44. Yoon SK, Seo YB, Im SJ, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int 2014:2-11.
45. Dandri M, Lütgehetmann M, Petersen J. Experimental animal models and therapeutic approaches for HBV. Semin Immunopathol 2013;35:7-21.
46. Koshinka AD, Jordhen L, Zhang E. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in mouse and woodchuck model. J Virol 2012;86:9297-310.
47. Tay SS, Wong YC, McDonald DM, et al. Antigen expression level threshold tunes the fate of CD8T cells during primary hepatic immune responses. Proc Natl Acad Sci USA 2014;111:E2540-9.
48. Pajot A, Michel ML, Fazilleau N, et al. A mousse model of human adaptative immune function HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 2004;34:3060-9.
49. Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F, et al. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a phase 2 study of patients with chronic hepatitis C infection. Gastroenterology 2014;147:119-31.
50. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cell after long-term effective therapy with nucleos(t)ides analogs. Gastroenterology 2012;143:963-73.
51. Raziorrough B, Schraut W, Gerlach T, et al. The immunoregulatory role of CD244 in chronic hepatitis B virus infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology 2010;52:1934-47.
52. Nebbia G, Peppa D, Schurich A, et al. Upregulation of the Tim3/galactin-9 pathway of T-cell exhaustion in chronic hepatitis B infection. PLoS ONE 2012;7:e47648.